Product Description

Free fatty acid receptor 4 (FFA4), also known as GPR120, is a G protein-coupled receptor sensitive to long-chain unsaturated fatty acids, particularly omega-3 fatty acids. It is widely expressed in intestinal enteroendocrine cells, adipose tissue, macrophages, and the liver. Its core function is to serve as a critical integrator of metabolism and inflammation: in the gut, it mediates GLP-1 secretion to regulate blood sugar and appetite; in adipose tissue and the liver, it promotes insulin sensitization and improves metabolic homeostasis; in macrophages, it exerts potent anti-inflammatory effects by suppressing inflammatory pathways. Consequently, FFA4 is a key molecule linking nutritional signals, metabolic regulation, and chronic inflammation, making it a promising therapeutic target for metabolic-inflammatory diseases such as type 2 diabetes, obesity, and non-alcoholic fatty liver disease.

ScreeningBio’s human FFA4 β-arrestin cell line is an ideal tool for studying GPCR/β-arrestin interactions. In this system, the GPCR C-terminus is fused to a smallBiT tag, and the β2-arrestin N-terminus is fused to a largeBiT tag. Upon receptor activation, GPCR/β-arrestin interaction brings the two fragments together to reconstitute an active NanoLuc enzyme, which can be quantified using the NanoBiT substrate. This cell line is designed to evaluate a compound’s ability to activate the β-arrestin signaling pathway.